Pharmacy | July 24, 2019

FDA Approves Generic Lyrica® Pregabalin

One of the most talked-about drug patents in workers’ compensation, Pfizer’s Lyrica® (pregabalin), patent extensions ended on July 1, 2019. 

Lyrica (pregabalin) is one of the most commonly prescribed drugs for neuropathic pain. The drug was first approved for use in 2004 and has since seen several patent extensions. Lyrica was the 15th top selling drug of 2018, with sales totaling $4.97 billion.

On July 19, 2019, the FDA gave nine manufacturers the ability to market different strengths of pregabalin. Mitchell anticipates these versions of pregabalin will push prices down. The FDA noted, “today’s approval of the first generics for pregabalin, a widely-used medication, is another example of the FDA’s longstanding commitment to advance patient access to lower cost, high-quality generic medicines.” (FDA)

Approvals went to: Alembic Pharmaceuticals, Alkem Laboratories, Amneal Pharmaceuticals, Dr. Reddy’s Laboratories, InvaGen Pharmaceuticals, MSN Laboratories Ltd., Rising Pharmaceuticals, Inc., Sciegen Pharmaceuticals Inc., and Teva Pharmaceuticals.

The Latest in

Filter By

Related News

{{ArticleCategory(article)}} MPower

{{article.Title}}

@Mitchell_Intl

{{article.ShortDescription | text}}

More News

Four essential investments your shop must make to continue competing over the long term. https://t.co/ZI05MANDhu Four essential investments your shop must make to continue competing over the long term. https://bit.ly/2P68O8R
Learn the lingo from our automation glossary of terms and see how these technologies are being applied in insurance, P&C claims, and collision repair industries. https://t.co/tfZ7DI9jo6 Learn the lingo from our automation glossary of terms and see how these technologies are being applied in insurance, P&C claims, and collision repair industries. https://bit.ly/39SPunB
With this new wave of V2V technology and connectivity comes unprecedented challenges as well as opportunities, especially as it relates to the data generated by today’s modern vehicles. https://t.co/vLWDz1E0f4 With this new wave of V2V technology and connectivity comes unprecedented challenges as well as opportunities, especially as it relates to the data generated by today’s modern vehicles. https://bit.ly/2LlgP6T
What does Level 3 Automation mean for diagnostics and collision claims? https://t.co/tBBFgeZRIg What does Level 3 Automation mean for diagnostics and collision claims? https://bit.ly/2N4s9o7
The @AmerMedicalAssn 2020 #CPTcode set is here. Learn about the 394 code changes and their impact on the casualty industry. https://t.co/PoDMM38Nbq The @AmerMedicalAssn 2020 #CPTcode set is here. Learn about the 394 code changes and their impact on the casualty industry. https://bit.ly/2vLkwOi
“We are more than happy to share our model,” explains @NYBCF CFO and COO, Dave Perine, “certainly there’s a lot of interest that’s been generated, especially with the tremendous growth of gig economy.” https://t.co/7yVuo66KKb “We are more than happy to share our model,” explains @NYBCF CFO and COO, Dave Perine, “certainly there’s a lot of interest that’s been generated, especially with the tremendous growth of gig economy.” https://bit.ly/33hcMiL
From a drug-therapy perspective, current alternatives to opioids include NSAIDs, anticonvulsants and occasionally certain antidepressants. https://t.co/loOG8SWN6w From a drug-therapy perspective, current alternatives to opioids include NSAIDs, anticonvulsants and occasionally certain antidepressants. https://bit.ly/2Og777A
The mPower Awards recognize companies like @Westfield1848 and @NYBCF in the P&C and collision repair world for innovative new services or process transformations. Learn about their stories and how to nominate for the 2020 awards. https://t.co/ZsUN8dXNn5 The mPower Awards recognize companies like @Westfield1848 and @NYBCF in the P&C and collision repair world for innovative new services or process transformations. Learn about their stories and how to nominate for the 2020 awards. https://bit.ly/2N4yCj6
"Emotion AI might be used to gain a better understanding of user frustrations and pain points, helping to guide improvements that streamline and simplify the P/C insurance claims process." https://t.co/j5h4HeVvOj via @CarrierMgmt "Emotion AI might be used to gain a better understanding of user frustrations and pain points, helping to guide improvements that streamline and simplify the P/C insurance claims process." https://bit.ly/2sJBZoW via @CarrierMgmt
Technology-enabled services can provide a variety of benefits to claims organizations including flexibility, scalability and easier integration processes. https://t.co/oDhgVcly5A Technology-enabled services can provide a variety of benefits to claims organizations including flexibility, scalability and easier integration processes. https://bit.ly/2TwYB7o
Celebrate success! The Mitchell mPower Awards recognize companies for their innovative approaches to supporting the Property & Casualty and collision repair industries. Know someone that fits the description? Nominate them here - https://t.co/Eacgczii5B https://t.co/SeFJPK3TE2 Celebrate success! The Mitchell mPower Awards recognize companies for their innovative approaches to supporting the Property & Casualty and collision repair industries. Know someone that fits the description? Nominate them here - https://bit.ly/2PdN2Ql

Three Tips for Pharmacy Program Optimization in 2020. https://t.co/y7aE4FhZnG @WorkCompWire Three Tips for Pharmacy Program Optimization in 2020. https://bit.ly/2Hf4y1B @WorkCompWire
We outline how the new Michigan auto fee schedule will work and what carriers need to know now based on our current understanding of the bill. https://t.co/rAaORFYmTT We outline how the new Michigan auto fee schedule will work and what carriers need to know now based on our current understanding of the bill. https://bit.ly/38TG8qk
The latest mPower Newsletter is now available, featuring articles on claims market predictions and glass repair in 2020, #gabapentinoids in #workerscomp, advanced claims reporting and an automation glossary for the P&C industry. Read the newsletter here - https://t.co/y4UVKyOBY4 https://t.co/DCOpHVPfqw The latest mPower Newsletter is now available, featuring articles on claims market predictions and glass repair in 2020, #gabapentinoids in #workerscomp, advanced claims reporting and an automation glossary for the P&C industry. Read the newsletter here - https://bit.ly/37BspEj

Our 2020 #workerscomp predictions around #opioids, #medicare and #medicalmarijuana. https://t.co/7KYdYO72IG Our 2020 #workerscomp predictions around #opioids, #medicare and #medicalmarijuana. https://bit.ly/2tV38GF

Terms of Use | Privacy Practices | Copyright & Usage | [+} Report a Problem
© 2019 Mitchell International, Inc. All Rights Reserved.
By accessing Mitchell.com, each user agrees that they have read and agreed to be bound by the
Terms and Conditions governing Mitchell.com and Privacy Policies governing Mitchell.com.


paykasa bozdurma paykwik bozdurma